Results are highly cyclical for RC, so multiple-based fair value is less reliable here.
| FY | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| High | 20.96 | 19.38 | 18.20 | 15.36 | 16.10 | 17.15 | 16.52 | 16.86 | 16.60 | 16.26 | 13.49 | 10.23 | 7.05 |
| Low | 15.66 | 16.00 | 13.24 | 12.50 | 13.10 | 13.60 | 13.77 | 3.99 | 11.38 | 9.75 | 9.25 | 6.71 | 2.17 |
| Rev/Sh | 0.35 | 1.78 | 2.03 | 2.76 | 5.22 | 5.39 | 2.70 | 4.65 | 4.99 | 4.19 | 2.27 | 5.31 | 1.52 |
| Chg/Yr | — | +404% | +14% | +36% | +89% | +3% | -50% | +72% | +7% | -16% | -46% | +134% | -71% |
| Div | 2.12 | 1.54 | 1.52 | 1.49 | 1.48 | 1.51 | 1.52 | 1.30 | 1.66 | 1.66 | 1.46 | 1.10 | 0.39 |
Fair value (3.2x sales) multiplies each year's revenue per share by the price-to-sales ratio investors have typically paid for RC — the median of the last 20 fiscal years' average price over that year's revenue per share. The line extends forward with analyst revenue estimates (dashed).
Revenue comes from reported quarters; share counts come from market value divided by the share price, so buybacks and splits are handled correctly. The verdict calls a stock over- or undervalued only when the price sits more than 10% from the line.